2. Academic Validation
  3. LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p

LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p

  • Aging (Albany NY). 2019 Nov 13;11(21):9794-9810. doi: 10.18632/aging.102427.
Honghai Song 1 2,  Jiaming Liu 2 3,  Xin Wu 2,  Yang Zhou 2,  Xuanyin Chen 2,  Jiangwei Chen 2,  Keyu Deng 4,  Chunxia Mao 4,  Shanhu Huang 2,  Zhili Liu 1 2
Affiliations

Affiliations

  • 1 Department of Science and Technology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
  • 2 Department of Orthopedic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
  • 3 Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
  • 4 The National Engineering Research Center for Bioengineering Drugs and Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, China.
PMID: 31724536 DOI: 10.18632/aging.102427
Abstract

The transcript factor LHX2 is dysregulated in many cancers but its role in osteosarcoma (OS) remains unclear. In this study, we confirm that LHX2 is up-regulated in osteosarcoma, and that its silencing inhibits OS malignancy and induces Autophagy via mTOR signaling. We further demonstrate that miR-129-5p negatively regulates LHX2 and suppresses the malignant phenotypes of OS. LHX2 overexpression could restore the malignant phenotypes. In conclusion, LHX2 regulates tumorigenesis and Autophagy via mTOR in OS and is negatively regulated by miR-129-5p. Targeting the miR-129-5p/LHX2/mTOR axis therefore represents a novel therapeutic strategy for OS treatment.

Keywords

LHX2; autophagy; mTOR pathway; miR-129-5p; osteosarcoma.

Figures
Products